BGPT: Paper Review: Non-enzymatic Lysine Lactoylation of Glycolytic Enzymes

Explore by Goal

Quick Explanation Copied

Key claim:

They identify a non-enzymatic LactoylLys PTM produced from the glyoxalase-pathway intermediate lactoylglutathione (LGSH), show it is enriched on glycolytic enzymes, and report a GLO2-loss state with elevated LGSH/LactoylLys and reduced glycolytic metabolite output—proposing a metabolite-driven feedback brake on glycolysis under high MGO/Warburg-like conditions.

Long Explanation

Paper Review (Critical, Science-First): Non-enzymatic Lysine Lactoylation of Glycolytic Enzymes

DOI: 10.1016/j.chembiol.2019.11.005

Published: Nov 22, 2019 (as extracted from the provided full-text XML).

Visual Map of the Proposed Mechanism (Writer = LGSH; Trigger = MGO; Gate = GLO2)

Evidence Anchors (What is directly shown in the study vs what is inferred)

Shown: LGSH can generate LactoylLys via non-enzymatic acyl transfer in vitro (recombinant histone H4 incubated with LGSH shows LactoylLys; with MGO shows different Arg-derived products instead).
Shown: GLO2 loss elevates LGSH and LactoylLys (and reduces GSH), while GLO1/GLO1+GLO2 losses remove the LactoylLys rise, linking LactoylLys abundance to LGSH availability rather than MGO alone.
Shown: Reactivity-based proteome profiling identifies ~350 LactoylLys-modified proteins and enrichment on carbon metabolism/glycolysis pathways.
Shown (but mechanism not fully closed): Targeted metabolomics in cells indicates a relative decrease in glycolytic metabolites downstream of DHAP/GA3P in GLO2−/− (and exacerbated with MGO), consistent with “functional regulation of glycolysis,” but the causal chain from specific LactoylLys sites to specific enzyme rate changes is not fully demonstrated in the provided text.

Quantitative Snapshots (From explicit values in the provided paper text)

Core Idea: Metabolite-derived, chemistry-driven PTM as metabolic “brake”

The study frames LactoylLys as a non-enzymatic Lys modification driven by LGSH, analogous (in conceptual logic) to known chemistry where reactive acyl donors can form lysine adducts without canonical lysine acetyltransferases/deacetylases. They explicitly connect their mechanism to prior work on non-enzymatic lysine acetylation from acetyl-CoA (via a proximal S-acylated thiol intermediate) and the broader idea that metabolite-derived dicarbonyls and related electrophiles can modify proteins.

Methodological Strengths (and why they matter)

1) Chemical distinguishability of isomers (LactoylLys vs CEL/MGO-derived Arg PTMs)

The study uses authentic/reference standards and reports chromatographic separation for quantitation of LactoylLys relative to isomeric CEL, using a deuterated internal standard for CEL. This directly reduces (though may not eliminate) the risk of mass/isomer confusion when interpreting non-enzymatic PTMs from electrophile chemistry.

2) Genetic perturbation of LGSH production/removal (GLO1, GLO2, and combined KO)

Using CRISPR-generated knockouts directly tests dependence on the glyoxalase pathway intermediate rather than relying purely on exogenous electrophile dosing.

3) Targeted metabolomics to connect PTMs to pathway flux

The authors measure glycolytic metabolite shifts in GLO2−/− and interpret the pattern as downstream depression (DHAP/GA3P-proximal region), and they claim upstream glycolysis and TCA/cofactors are not broadly perturbed, which helps constrain alternative explanations.

Skeptical Critique: likely blind spots / uncertainties

A) Chemical labeling and high-dose electrophile paradigms may overemphasize pathways active under stress conditions

The study uses large exogenous perturbations (e.g., 50 mM MGO/alkMGO for hours; and cell culture glucose experiments with 0/5/25 mM for 24h). While the authors interpret these as mimicking hyperglycemic/Warburg-like conditions, the extent to which the quantitative PTM landscape matches physiological dicarbonyl flux distributions is not proven in the provided excerpt. This is a general concern for non-enzymatic PTM chemistry because electrophile speciation, pH, redox state, and local microenvironments can shift reaction rates.

B) “Enriched on glycolytic enzymes” ≠ “LactoylLys causes the metabolite phenotype” (causal chain still incomplete)

The paper combines (i) enrichment statistics and (ii) a metabolomics phenotype. But the provided text does not show a site-specific enzymology experiment demonstrating that LactoylLys at specific glycolytic Lys sites decreases catalytic rates of those enzymes under controlled, matched conditions. Without that, the metabolomics decrease could also reflect broader glyoxalase/GSH system remodeling, altered redox buffering, or changes in protein stability/turnover.

C) Proteomics bias: detection sensitivity can favor abundant/soluble proteins and specific PTM chemistries

Reactivity-based profiling with an alkynyl MGO analog and downstream enrichment can bias toward proteins with accessible Lys/Cys microenvironments and proteins that efficiently capture click-labels. The authors do pathway analysis, but enrichment may partly reflect assay chemistry preferences rather than true in vivo occupancy.

How this fits the field (and what it builds on)

The study extends the theme that metabolite electrophiles can create covalent protein modifications that influence signaling and homeostasis. For instance, MGO-derived modifications can activate KEAP1-NRF2 signaling when MGO load rises.
It also leverages the established glyoxalase cycle biology (GLO1 converts MGO-related adducts to stable LGSH, while GLO2 hydrolyzes LGSH to recycle glutathione and generate D-lactate), using this cycle to define where the “writer” substrate comes from.
Conceptually, their mechanism is analogous to other non-enzymatic acylation chemistries involving reactive acyl donors and thiol intermediates, as previously shown for acetyl-CoA-derived N-acetylation of lysines.

Potential falsifiers (what would most directly disprove the proposed feedback brake)

LGSH-dependence failure: If LactoylLys abundance does not track LGSH generation/removal when GLO1/GLO2 are perturbed (within matched MGO backgrounds), then LGSH would not be a driver.
Enzyme activity mismatch: If purified glycolytic enzymes do not show reduced activity after controlled LactoylLys incorporation (or if phospho/other PTM changes explain the phenotype), the “LactoylLys regulates glycolysis” statement would be undermined.
Assay-chemistry artifact: If the same enrichment pattern is not reproduced with orthogonal LactoylLys detection/orthogonal labeling strategies that avoid the alkMGO-click enrichment step, then the detected PTM landscape may be partly methodological.

Reproducibility & Data availability (based on the provided text)

Proteomics inventory availability: They state the proteomics inventory is available on Mendeley (https://doi.org/10.17632/9ccms3gnf6.2).

Methods detail: The provided excerpt includes substantial STAR+METHODS style methodological detail (CRISPR cloning approach at the level of gRNA targeting and knockout validation by RFLP/sequencing; dosing; in vitro incubation; MS acquisition logic; metabolomics workflow).

Paper-level scoring (skeptical, evidence-weighted)

Note: this “radar” uses heuristic values consistent with the fields below; it is not an external metric.

Author review links (bespoke) — click any for deeper critique

Feedback:

Updated: April 28, 2026